AbstractPurpose of review
With ageing populations, the prevalence of multimorbidity is increasing. This review discusses recent developments in the understanding of multimorbidity in the context of chronic kidney disease (CKD). It explores the associated treatment burden and the implications for key outcomes and patient care.Recent findings
Comorbidity and polypharmacy are common in CKD, even at early stages, and are associated with significant treatment burden. Both ‘concordant’ and ‘discordant’ comorbidities have a negative impact on mortality, cardiovascular disease, hospitalisation and length of stay. In addition, quality of life is influenced by many factors beyond CKD, including comorbidities and certain medications. Several factors may reduce treatment burden for people with CKD, though research on this is at an early stage. Although patient activation is desirable to support self-management amongst people with multimorbidity, there are significant challenges that impact patient capacity amongst elderly populations with complex needs.Summary
Comorbidities are common in CKD and have important implications for patients, clinicians and health services.